BioNTech SE
NASDAQ:BNTXBiotechnology
-$1.41 today
- Market cap
- $20.64B
- Beta
- 1.32
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$4.93
Volume 1.24M
Average 1.11M
BNTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
BioNTech SENASDAQ: BNTX
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 5.2% from a year ago
Cash & equivalents stood at €9.74B at the end of Q2 FY2026, down 5.2% from a year earlier and down 2.1% from the prior quarter. Over 3 fiscal years it compounded at -17.9% a year.
Context
- Cash & equivalents amounted to 47.9% of total assets at the end of Q2 FY2026, up 0.4 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -5.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
EUR · from the balance sheet
- Latest · FY2025
- 7.67B EUR
- Year-over-year change
- -21.4%
- 4-year CAGR
- +45.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.67B | -21.4% |
| FY2024 | 2024-12-31 | 9.76B | -16.3% |
| FY2023 | 2023-12-31 | 11.66B | -15.9% |
| FY2022 | 2022-12-31 | 13.88B | +719.7% |
| FY2021 | 2021-12-31 | 1.69B | — |
Cash & Equivalents vs competitors
How BNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -5.2% is the 7th highest of 11, against a peer median of -2.3%.
- Cash & equivalents amounts to 47.9% of total assets for BNTX, versus a peer median of 19.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €9.74B EUR | -5.2% | -17.9% | 47.9% | |
| Jun 2026 | $3.98B USD | +103.7% | +1.6% | 50.6% | |
| Jun 2026 | $1.5B USD | +16.0% | -44.3% | 12.0% | |
| Mar 2026 | $452.68M USD | -5.1% | +5.1% | 42.2% | |
| Sep 2026 | $429.38M USD | +479.6% | -8.2% | 27.0% | |
| Mar 2026 | €301.65M EUR | +24.2% | +32.5% | 55.5% | |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Sep 2026 | $57.93M USD | -63.4% | -11.1% | 5.8% | |
| Sep 2026 | $45.08M USD | -25.2% | -5.5% | 7.4% | |
| Jun 2026 | $44.66M USD | +0.5% | +0.1% | 6.2% | |
| Mar 2026 | $12.44M USD | -14.7% | +101.6% | 8.5% | |
| Peer median (excluding BNTX) | — | -2.3% | -2.7% | 19.5% | |
Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.69B | 13.88B | 11.66B | 9.76B | 7.67B |
| Short-term Investments | 381.6M | 189.4M | 4.89B | 7.02B | 7.16B |
| Net Receivables | 12.38B | 7.15B | 2.34B | 1.52B | 984.48M |
| Inventory | 502.5M | 439.6M | 357.7M | 283.3M | 110.65M |
| Other Current Assets | 113.4M | 271.9M | 280.9M | 212.7M | 210.71M |
| Total Current Assets | 15.07B | 21.92B | 19.53B | 18.8B | 16.14B |
| Property, Plant & Equipment (Net) | 520.4M | 821.1M | 971.6M | 1.18B | 1.29B |
| Goodwill | 57.8M | 61.2M | 362.5M | 380.6M | 367.74M |
| Intangible Assets | 144.6M | 158.5M | 804.1M | 790.4M | 1.61B |
| Long-term Investments | 21.3M | 80.2M | 1.18B | 1.25B | 2.49B |
| Tax Assets | 0 | 229.6M | 81.3M | 81.7M | 13.49M |
| Other Non-current Assets | 14.4M | 6.5M | 83.4M | 36.1M | 76.97M |
| Total Non-current Assets | 758.5M | 1.36B | 3.48B | 3.73B | 5.84B |
| Total Assets | 15.83B | 23.28B | 23.01B | 22.53B | 21.98B |
| Account Payables | 160M | 204.1M | 354M | 426.7M | 534.67M |
| Short-term Debt | 129.9M | 36M | 28.1M | 39.5M | 52.18M |
| Tax Payables | 1.57B | 595.9M | 525.5M | 4.5M | 0 |
| Deferred Revenue | 186.1M | 77.1M | 353.3M | 294.9M | 754.58M |
| Other Current Liabilities | 1.44B | 2.04B | 809.6M | 1.76B | 734.39M |
| Total Current Liabilities | 3.48B | 2.95B | 2.07B | 2.52B | 2.14B |
| Long-term Debt | 171.6M | 176.2M | 191M | 214.7M | 29.89M |
| Deferred Tax Liabilities | 66.7M | 6.2M | 39.7M | 42.4M | 84.26M |
| Deferred Revenue (Non-current) | 9M | 48.4M | 398.5M | 183M | 87.96M |
| Other Non-current Liabilities | 208.2M | 42.1M | 60.7M | 155.3M | 234.5M |
| Total Non-current Liabilities | 455.5M | 272.9M | 689.9M | 595.4M | 621.84M |
| Total Liabilities | 3.94B | 3.22B | 2.76B | 3.12B | 2.76B |
| Common Stock | 246.3M | 248.6M | 248.6M | 248.6M | 258.89M |
| Retained Earnings | 9.88B | 18.83B | 19.76B | 19.1B | 17.95B |
| Accumulated OCI | 93.9M | (848.9M) | (984.6M) | (1.33B) | (1.46B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 11.89B | 20.06B | 20.25B | 19.41B | 19.22B |
| Total Debt | 301.5M | 212.2M | 219.1M | 254.2M | 267.29M |
| Net Debt | (1.39B) | (13.66B) | (11.44B) | (9.51B) | (7.4B) |
BioNTech SE
NASDAQ:BNTX
Intrinsic Alpha fair value
Locked
Current Price
$83.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.